From: Morton, Ben

Friday, 12 March 2021 8:44 AM Sent:

To: **DLO Morton**

Subject: Fwd: COVID-19 Daily Media Report - Friday 12 March 2021

THE HON BEN MORTON MP

ASSISTANT MINISTER TO THE PRIME MINISTER AND CABINET ASSISTANT MINISTER TO THE MINISTER FOR THE PUBLIC SERVICE ASSISTANT MINISTER FOR ELECTORAL MATTERS

6 Aveley Street, WILLETTON WA 6155 | PO Box 329, WILLETTON WA 6955

T: 08 9354 9633 Public E: ben.morton.mp@aph.gov.au | W: benmorton.net.au

(Please note that this email is sent from a private email address for the use of the recipient only)

Begin forwarded message:

From: Daily Media Reports

Date: 12 March 2021 at 5:32:37 am AEDT To: COVID-19 Daily Media Report

Subject: FW: COVID-19 Daily Media Report - Friday 12 March 2021

From: noreply@streem.com.auOn Behalf OfNational COVID-19 Commission Advisory Board via

Sent: Friday, 12 March 2021 5:30:03 AM (UTC+10:00) Canberra, Melbourne, Sydney

To: Daily Media Reports

Subject: COVID-19 Daily Media Report - Friday 12 March 2021

View this email online



National **COVID-19 Commission Advisory Board**

DAILY COVID-19 BRIEFING

Friday 12 March 2021





Download Media Items in PDF



Download Media Items in Plain Text


Open Viewer for more news

Jump to: National COVID-19 Commission Advisory Board (3) | Business & Economy (5) | Sector Issues (6) | Community Impact (2) | Federal (5) | NSW (4) | VIC (3) | QLD (5) | SA (4) | NT (1) | TAS (2) | WA (1) Global Response (5)

Good morning - please find the latest COVID-19 related coverage below.

Stay up to date with the national impact and response with the Australian Government's <u>current status site</u>.

Below you will find each state and territory's specific updates and responses to the pandemic: <u>NSW | Victoria | Queensland | ACT | South Australia | Western Australia | Northern Territory | Tasmania</u>



s 22(1)

From: Daily Media Reports

Sent: Thursday, 1 April 2021 4:31 AM **To:** PMC Daily Media Report

Subject: FW: Daily Media Briefing Thursday 1 April 2021

From: noreply@streem.com.auOn Behalf OfPrime Minister and Cabinet via Streem **Sent:** Thursday, 1 April 2021 4:30:04 AM (UTC+10:00) Canberra, Melbourne, Sydney

To: Daily Media Reports

Subject: Daily Media Briefing Thursday 1 April 2021

View this email online



DAILY MEDIA BRIEFING

Thursday 1 April 2021

•	Pfizer says its COVID vaccine is safe and 100% effective in preventing the illness in young people
	aged 12 to 15. Pfizer hopes that vaccinations of the group could begin before the next school year,
	Albert Bourla, Pfizer's chair and chief executive said in a statement. In the trial of 2,260 adolescents
	aged 12 to 15, there were 18 COVID-19 cases in the group that got a placebo shot, and none in the
	group that got the vaccine, resulting in 100% efficacy in preventing COVID-19.

s 22(1)(a)(ii)

From: Daily Media Reports

Sent: Thursday, 1 April 2021 5:31 AM **To:** COVID-19 Daily Media Report

Subject: FW: COVID-19 Daily Media Report - Thursday 1 April 2021

From: noreply@streem.com.auOn Behalf OfNational COVID-19 Commission Advisory Board via Streem

Sent: Thursday, 1 April 2021 5:30:04 AM (UTC+10:00) Canberra, Melbourne, Sydney

To: Daily Media Reports

Subject: COVID-19 Daily Media Report - Thursday 1 April 2021

View this email online




National COVID-19 Commission Advisory Board

DAILY COVID-19 BRIEFING

Thursday 1 April 2021





s 22(1)(a)(ii)

From: Daily Media Reports

Sent: Monday, 12 April 2021 5:32 AM **To:** COVID-19 Daily Media Report

Subject: FW: COVID-19 Daily Media Report - Monday 12 April 2021

From: noreply@streem.com.auOn Behalf OfNational COVID-19 Commission Advisory Board via Streem

Sent: Monday, 12 April 2021 5:30:02 AM (UTC+10:00) Canberra, Melbourne, Sydney

To: Daily Media Reports

Subject: COVID-19 Daily Media Report - Monday 12 April 2021

View this email online



National COVID-19 Commission Advisory Board

DAILY COVID-19 BRIEFING Monday 12 April 2021





From: DLO

To: s 22(1)(a)(ii) ; Neil, John

Cc: s 22(1)(a)(ii) ; <u>Steel, Lee; Grigson, Paul; Frame, Alison;</u> s 22(1)(a)(ii) s 22(1)(a)(ii) <u>DLO</u>

Subject: RE: Draft letter to Pfizer [SEC=OFFICIAL:Sensitive]

Date: Wednesday, 5 May 2021 8:24:39 AM

Attachments: Joint letter - PM and Hunt to Bourla - Delivery of Pfizer vaccinations.pdf

OFFICIAL: Sensitive

ΑII

Please find attached signed letter to Dr Bourla.

nt's office now to distribute.

s 22(1)(a)(ii)

Departmental Liaison Officer

Office of the Prime Minister, the Hon Scott Morrison MP

MG 8, Parliament House, Canberra ACT 2600

s 22(1)(a)(ii)

e. s 47E(d) s 22(1)(a)(ii)

From: s 22(1)(a)(ii)

Sent: Tuesday, 4 May 2021 5:38 PM

To: Neil, John

Cc: s 22(1)(a)(ii) ; Steel, Lee; Grigson, Paul; Frame, Alison; s 22(1)(a)(ii)

DLO

Subject: Re: Draft letter to Pfizer [SEC=OFFICIAL:Sensitive]

Approved for e sig

Sent from my iPhone

On 4 May 2021, at 4:26 pm, Neil, John < John.Neil@pmc.gov.au > wrote:

OFFICIAL: Sensitive

Hi as discussed earlier, attached is a draft letter to Pfizer from the PM and Minister Hunt.

I understand this version will shortly go to Minister Hunt for his agreement and signature and then will come to you for the PM's approval.

Cheers

John

John Neil (he/him)| a/g Assistant Secretary | **Health COVID-19 Priorities** Social Policy Division | **Department of the Prime Minister and Cabinet**

T: s 22(1)(a)(ii) | E: john.neil@pmc.gov.au

OFFICIAL: Sensitive

Dr Albert Bourla, DVM, PH.D. Chairman and Chief Executive Officer Pfizer Inc. 235 East 42nd Street NEW YORK CITY NY 10017

Dear Dr Bourla

I would firstly like to congratulate Pfizer on the success of your COVID-19 vaccine supply and distribution strategy. Australia is grateful for the constructive engagement with your Australian team and the support they have provided for our domestic vaccination program.

The supply of the more than 40 million doses of the Pfizer mRNA vaccine in 2021 is fundamental to the success of our program.

Noting the levels of demand for your vaccine around the world, the recent statements from the US administration in relation to the export of products are a welcome development that will increase vaccine availability globally. The success of the US rollout and the ability for the US to make doses available to the rest of the world, is a testament to the supply of Pfizer vaccines to support the US rollout.

Given this increase in global supply, I am writing ask for delivery of some of our purchased doses to be brought forward.

s 45

The combined effect of the export restrictions in Europe and the adverse events associated with the AstraZeneca vaccine, has meant that the Pfizer vaccine is the only vaccine currently approved and recommended for more than half of Australian adults including many who are particularly vulnerable to severe disease from COVID-19. This is now having the direct result that Australia's most vulnerable populations may not be fully protected before the onset of winter.

s 45

s 45

OFFICIAL: Sensitive

s 45

I thank you for your consideration of our urgent request and look forward to continuing our important partnership with Pfizer Inc.

Yours sincerely

SCOTT MORRISON

GREG HUNT

From: Neil, John
To: DLO

Subject: RE: Letter from the Hon Scott Morrison MP and the Hon Greg Hunt MP [SEC=OFFICIAL]

Date: Wednesday, 5 May 2021 11:07:36 AM

Attachments: image001.png

OFFICIAL

Thanks \$ 22(1) (and thanks for following this up last night and this morning and getting it signed!)

Cheers John

From: DLO

Sent: Wednesday, 5 May 2021 10:08 AM

To: s 22(1)(a)(ii) ; Neil, John

Cc: s 22(1)(a)(ii) ; Steel, Lee; Grigson, Paul; Frame, Alison; s 22(1)(a)(ii)

DLO

Subject: FW: Letter from the Hon Scott Morrison MP and the Hon Greg Hunt MP [SEC=OFFICIAL]

OFFICIAL

H s 22(1) , John

For awareness, the letter has been sent to Anne Harris, Managing Director, Pfizer Australia & New Zealand, for the attention of Dr Bourla.

Regards

s 22(1)(a)(ii)

Departmental Liaison Officer

Office of the Prime Minister, the Hon Scott Morrison MP

MG 8, Parliament House, Canberra ACT 2600

s 22(1)(a)(ii)

e s 47E(d) s 22(1)(a)(ii)

From: Minister Hunt < Minister. Hunt@health.gov.au >

Sent: Wednesday, 5 May 2021 9:33 AM

To: s 47G(1)(a)

Cc: s 47G(1)(a)

Subject: Letter from the Hon Scott Morrison MP and the Hon Greg Hunt MP [SEC=OFFICIAL]

Dear Ms Harris,

Please see attached letter from the Prime Minister, the Hon Scott Morrison MP, and the Minister for Health and Aged Care, the Hon Greg Hunt MP, for the attention of Dr Bourla.

Best regards

s 47E(d)

Departmental Liaison Officer

Office of the Hon Greg Hunt MP | Minister for Health and Aged Care

S 47E(d)S 47E(d)

Suite M1.41, PO Box 6022, Parliament House, Canberra ACT 2600, Australia

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

From: DLO

To: <u>Pullen, Victoria</u>

Cc: DLO

Subject: FW: Letter from the Hon Scott Morrison MP and the Hon Greg Hunt MP [SEC=OFFICIAL]

Date: Wednesday, 5 May 2021 12:36:01 PM

Attachments: image001.png

Joint letter - PM and Hunt to Bourla - Delivery of Pfizer vaccinations.pdf

OFFICIAL

Morning,

As discussed, please see Pfizer letter attached

Kind regards

s 22(1)(a)(ii)

From: DLO

Sent: Wednesday, 5 May 2021 10:08 AM

To: s 22(1)(a) ; Neil, John

Cc: s 22(1)(a)(ii) ; Steel, Lee ; Grigson, Paul ; Frame, Alison ; s 22(1)(a)(ii)

in, I adi, I famic, Alison,

DLO

Subject: FW: Letter from the Hon Scott Morrison MP and the Hon Greg Hunt MP [SEC=OFFICIAL]

OFFICIAL

Hi Alex, John

For awareness, the letter has been sent to Anne Harris, Managing Director, Pfizer Australia & New Zealand, for the attention of Dr Bourla.

Regards s 22(1)(a)(ii)

Departmental Liaison Officer

Office of the Prime Minister, the Hon Scott Morrison MP

MG 8, Parliament House, Canberra ACT 2600

p. (s 22(1)(a)(ii)

s 47E(d) s 22(1)(a)(ii)

From: Minister Hunt < Minister. Hunt@health.gov.au >

Sent: Wednesday, 5 May 2021 9:33 AM

To: s 47G(1)(a)

Cc: s 47G(1)(a)

Subject: Letter from the Hon Scott Morrison MP and the Hon Greg Hunt MP [SEC=OFFICIAL]

Dear Ms Harris,

Please see attached letter from the Prime Minister, the Hon Scott Morrison MP, and the Minister for Health and Aged Care, the Hon Greg Hunt MP, for the attention of Dr Bourla.

Best regards

s 22(1)(a)(ii)

Departmental Liaison Officer

Office of the Hon Greg Hunt MP | Minister for Health and Aged Care

S 22(1)(a)(ii)
S 47E(d)

Suite M1.41, PO Box 6022, Parliament House, Canberra ACT 2600, Australia

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

OFFICIAL: Sensitive



THE HON SCOTT MORRISON MP Prime Minister

THE HON GREG HUNT MP Minister for Health and Aged Care

4 May 2021

Dr Albert Bourla, DVM, PH.D. Chairman and Chief Executive Officer Pfizer Inc. 235 East 42nd Street NEW YORK CITY NY 10017

Dear Dr Bourla

I would firstly like to congratulate Pfizer on the success of your COVID-19 vaccine supply and distribution strategy. Australia is grateful for the constructive engagement with your Australian team and the support they have provided for our domestic vaccination program.

The supply of the more than 40 million doses of the Pfizer mRNA vaccine in 2021 is fundamental to the success of our program.

Noting the levels of demand for your vaccine around the world, the recent statements from the US administration in relation to the export of products are a welcome development that will increase vaccine availability globally. The success of the US rollout and the ability for the US to make doses available to the rest of the world, is a testament to the supply of Pfizer vaccines to support the US rollout.

Given this increase in global supply, I am writing ask for delivery of some of our purchased doses to be brought forward.

s 45

The combined effect of the export restrictions in Europe and the adverse events associated with the AstraZeneca vaccine, has meant that the Pfizer vaccine is the only vaccine currently approved and recommended for more than half of Australian adults including many who are particularly vulnerable to severe disease from COVID-19. This is now having the direct result that Australia's most vulnerable populations may not be fully protected before the onset of winter.

OFFICIAL: Sensitive

OFFICIAL: Sensitive

GREG HUNT

SCOTT MORRISON

OFFICIAL: Sensitive

s 22(1)(a)(ii)

From: Daily Media Reports

Sent: Monday, 12 July 2021 4:36 AM **To:** PMC Daily Media Report

Subject: FW: Daily Media Briefing Monday 12 July 2021

From: noreply@streem.com.auOn Behalf OfPrime Minister and Cabinet via Streem Sent: Monday, 12 July 2021 4:35:18 AM (UTC+10:00) Canberra, Melbourne, Sydney

To: Daily Media Reports


Subject: Daily Media Briefing Monday 12 July 2021

View this email online



DAILY MEDIA BRIEFING

Monday 12 July 2021



VIEW PDF



Senior business figures turned to former PM Kevin Rudd to intervene in bringing forward Australia's Pfizer vaccine supply

ABC News by By Sunday 11 July 2021, 7:19pm AEST

Former prime minister Kevin Rudd contacted Pfizer chairman and chief executive Albert Bourla directly at the end of June to see if anything could be done to expedite the delivery of vaccines to Australia.

VIEW ONLINE

Back to Top

s 22(1)(a)(ii)

s 22(1)

From: Daily Media Reports

Sent: Monday, 12 July 2021 5:31 AM

To: DPMC Departmental and Executive report

Subject: FW: DPMC Departmental and Executive Monday 12th July 2021

From: noreply@streem.com.auOn Behalf OfPrime Minister and Cabinet via Streem Sent: Monday, 12 July 2021 5:30:02 AM (UTC+10:00) Canberra, Melbourne, Sydney

To: Daily Media Reports


Subject: DPMC Departmental and Executive Monday 12th July 2021

View this email online



DPMC Departmental and Executive

Monday 12 July 2021



From: FOI
To: Harris, John

Cc: s 22(1)(a)(ii) s 47E(d) FOI

Subject: New PMO FOI request - PMO/2021/041 - \$ 47F - Communications re Procurement and Supply of

the Pfizer-BioNTech COVID-19 Vaccine [SEC=OFFICIAL]

 Date:
 Monday, 12 July 2021 5:52:27 PM

 Attachments:
 1. FOI-PMO-2021-041 - FOI Request.pdf

image001.png image002.png image003.png

OFFICIAL

Dear John

Please see attached a new FOI request received by the Department of the Prime Minister, on Saturday 3 July 2021, from \$ 47F in the following terms:

Any records dated 1 April 2020 to 12 July 2021that confirm verbal and written communication relating to the procurement and supply of the Pfizer-BioNTech Covid-19 Vaccine to Australia between;

- the Prime Minister and or,
- the Prime Ministers Office and or,
- any employee, officer or representative of either and;
- Dr Albert Bourla, Pfizer Inc. Chairman and CEO and or,
- any Senior Executive of Pfizer Inc. and or,
- any employee or representative of Pfizer Inc. and or,
- The Hon Kevin Rudd, 26th Prime Minister of Australia
- The Hon Greg Hunt

These records may include but are not limited to documents that provide details, specifically; dates, location, attendees, addressees, recipients, and organiser or author of;

- past and future meetings.
- meeting requests made.
- meeting requests denied.
- meetings cancelled.
- phone calls made.
- phone calls received.
- phone calls not taken.
- written phone messages.
- text messages.
- voice messages.
- email correspondence.
- calendar entries.
- written correspondence such as letters, fax.
- memos.
- formal contractual requests, amendments.
- purchase orders raised for the supply of the vaccine.
- any other documentation that confirms verbal or written communication relating to the procurement and supply of the Pfizer-BioNTech Covid-19 Vaccine to Australia.

Next steps

Once you have considered the terms of the FOI request, please let us know:

• If valid, are the terms of the FOI request sufficiently clear to enable identification of

relevant documents, if they exist?

- if such documents exist, do they satisfy the definition of 'official document of a Minister' in section 4 of the FOI Act?
- if the terms of the request are sufficiently clear, is the FOI request able to be processed without substantially and unreasonably interfering in the performance of the Prime Minister's functions?

Timeframes

If valid, the current due date for notifying the applicant of a decision in relation to the request is **11 August 2021.**

We would be happy to discuss this FOI request.

Kind regards

s 22(1)(a)(ii) | A/g Senior FOI Advisor

FOI and Privacy Section | Legal Policy Branch

Government Division | Department of the Prime Minister and Cabinet

s 22(1)(a)(ii) | FOI Team (02) 6271 5849 5 22(1)(a)(ii) | foi@pmc.gov.au

www.pmc.gov.au

One National Circuit Barton ACT 2600 | PO Box 6500 CANBERRA ACT 2600

From: s 47

To: FOI Subject: FOI Request

Date: Monday, 12 July 2021 1:05:02 PM

Please kindly supply the following;

Any records dated 1 April 2020 to 12 July 2021that confirm verbal and written communication relating to the procurement and supply of the Pfizer-BioNTech Covid-19 Vaccine to Australia between;

- · the Prime Minister and or.
- · the Prime Ministers Office and or,
- · any employee, officer or representative of either and;
- · Dr Albert Bourla, Pfizer Inc. Chairman and CEO and or,
- · any Senior Executive of Pfizer Inc. and or,
- · any employee or representative of Pfizer Inc. and or,
- · The Hon Kevin Rudd, 26th Prime Minister of Australia
- · The Hon Greg Hunt

These records may include but are not limited to documents that provide details, specifically; dates, location, attendees, addressees, recipients, and organiser or author of;

- · past and future meetings.
- · meeting requests made.
- · meeting requests denied.
- · meetings cancelled.
- · phone calls made.
- · phone calls received.
- · phone calls not taken.
- · written phone messages.
- · text messages.
- · voice messages.
- · email correspondence.
- · calendar entries.
- · written correspondence such as letters, fax.
- · memos.
- · formal contractual requests, amendments.
- $\boldsymbol{\cdot}$ purchase orders raised for the supply of the vaccine.
- any other documentation that confirms verbal or written communication relating to the procurement and supply of the Pfizer-BioNTech Covid-19 Vaccine to Australia.

Thanking you in advance for your assistance.

Kindest regards,

s 47F



PROTECTED

COVID-19 AM Snapshot – 5 September 2020 s 22(1)(a)(ii)

PROTECTED

s 22(1)(a)(ii)

International Update

Health

Media is reporting that "the chief executive of Pfizer has warned about the reputational risks of fast-tracking a
COVID-19 vaccine, as governments put pressure on pharmaceutical companies to deliver an inoculation to bring the
pandemic to an end. Albert Bourla said the US drugmaker would never submit any vaccine for authorisation before
it felt it was safe and effective." (Financial Times)

PROTECTED

From: PMC COVID-19

Subject: Morning Snapshot on COVID-19 Saturday 27 June [SEC=PROTECTED]

Date: Saturday, 27 June 2020 7:47:07 AM

Attachments: <u>image001.png</u>

image003.png image003.png image004.png

s 22(1)(a)(ii)

PM"s Morning Snapshot - COVID-19 - 27 June 2020.pdf

PROTECTED

The information in this briefing is provided for the intended recipient only and is not to be further forwarded.

Good morning,

Please find attached the following for Saturday 27 June 2020

Morning Snapshot

s 22(1)(a)(ii)

This report is not authorised for release outside of Commonwealth Agencies in the address group. A separate version of this report, tailored for the requirements of the States and Territories, is dispatched separately.

Kind regards,

Reports Team

Disaster Preparedness and Response

Department of the Prime Minister and Cabinet

1 National Circuit Barton ACT 2600 | PO Box 6500 CANBERRA ACT 2600





PROTECTED

COVID-19 AM Snapshot – 27 June 2020

s 22(1)(a)(ii)

PM&C

• Albert Bourla, **Chief Executive of Pfizer**, said the pharmaceutical company has prepared for a "conflict" between countries over distribution of a COVID-19 vaccine, by developing two separate manufacturing supply networks in the US and Europe. (FT)

s 22(1)(a)(ii)

PROTECTED

PM&C




PROTECTED

COVID-19 Update – 4 September 2020 s 22(1)(a)(ii)

PROTECTED

PM&C



Health

s 22(1)(a)(ii)

International

s 22(1)(a)(ii)

Media is reporting that Pfizer Chief Executive [Albert Bourla] "has warned about the reputational risks of fast-tracking a COVID-19 vaccine, as governments put pressure on pharmaceutical companies to deliver an inoculation to bring the pandemic to an end." (FT) s 22(1)(a)(ii)

s 22(1)(a)

From: DLO

Sent: Thursday, 1 July 2021 9:30 AM

To: MCU - MinCorro

Cc: DLO; s 22(1)(a)(ii) Harris, John; COVID-19 Health Response Section

Subject: VIP - Rudd - Pfizer meeting [SEC=OFFICIAL]

Attachments: VIP - Rudd - Pfizer meeting.pdf

Follow Up Flag: Follow up Flag Status: Completed

Categories: VIPs only

OFFICIAL

Hi MCU

Please register the attached to the COVID Health team in SPD.

I expect NFA is fine but [S 22(1)] let us know if you'd like a response to this drafted.

Thanks

s 22(1)(a)(ii)

| Departmental Liaison Officer

Office of the Prime Minister, the Hon Scott Morrison MP

MG 8, Parliament House, Canberra ACT 2600

p. s 22(1)(a)(ii)

s 47E(d) s 22(1)(a)(ii)



The Honourable Kevin Rudd AC

26th Prime Minister of Australia

Hon Scott Morrison MP Prime Minister of Australia Parliament House, Canberra Email: \$ 47E(d)

Email:

30 June 2021

Dear Prime Minister Morrison,

As I mentioned to you earlier today, I had a scheduled call with Albert Bourla, Chairman and Chief Executive of Pfizer, Inc.

I used the call as an opportunity to congratulate Pfizer on their outstanding research and development and their success in producing so early a world-class COVID-19 vaccine. We also discussed Pfizer's current challenges and the political pressures they face around the world for an intellectual property waiver to expedite the supply of vaccines to developing countries. We follow these debates closely through our think tank operations in Washington – and Pfizer's ongoing negotiations with the United States Trade Representative.

I also used the call as an opportunity to ask Dr Bourla whether there was any possible way, given Pfizer's current international contractual obligations, to advance the dispatch of significant quantities of the Pfizer vaccine to Australia as early as possible in the third quarter this year. My understanding was that there were current contractual arrangements with the Australian Government to deliver a total 40 million doses by the end of 2021. I did so not as a representative of the Australian Government, but purely in my private capacity as an Australian citizen who cares for his country's wellbeing.

Dr Bourla indicated that they had limited flexibility because of their existing supply obligations around the world. Nonetheless, he also indicated that a number of their manufacturing facilities were producing ahead of schedule. In response to my representations, Dr Bourla said he would personally look at "what further might be able to be done". I thanked Dr Bourla for that.

Dr Bourla indicated that, if it became physically possible to bring forward delivery, he would require a further formal contractual request from the Australian Government to that effect. I replied that that was understandable. I added, of course, that would be a matter for the Australian Government and that I would pass this on to you.

Speaking on my own initiative, I floated the possibility of Australia perhaps seeking a large-scale advance order of Pfizer's 2022 vaccine "booster" which, from what I have read, is still under development. I speculated that it might perhaps be possible for the Australian Government to consider a commercial offer for the 2022 booster that would also incorporate a bringing-forward of the current order for the 2021 vaccine into the early part of the third quarter of this year.

Once again, I emphasised to Dr Bourla that this was speculation on my own part, rather than me acting in any way on behalf of the Australian Government.

As Dr Bourla lives in New York, we also agreed to catch up when I return there later this year.

Yours sincerely,

Hon Kevin Rudd AC